Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 11,176 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cohort study Clear all

Conditions: Solid Tumors
Interventions: ERY974; Drug
Lead sponsor: Chugai Pharmaceutical; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Boston, Massachusetts + 4 more

Conditions: Depression During Pregnancy
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Advanced Gastric Cancer
Interventions: IMM2902; Drug
Lead sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Boston, Massachusetts • Dallas, Texas • Fairfax, Virginia

Conditions: Locally Advanced/Metastatic Solid Tumors
Interventions: ISM3412; Drug
Lead sponsor: InSilico Medicine Hong Kong Limited; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Denver, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 2 more

Conditions: Endovascular Abdominal Aortic Aneurysm Repair (EVAR)
Interventions: Not listed
Lead sponsor: St. Joseph Mercy Oakland Hospital; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Pontiac, Michigan

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Type 2 Diabetes
Interventions: TODAY cohort; Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 15 Years and older
Enrollment: 517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 15
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 10 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Pembrolizumab, Carboplatin, Nab-paclitaxel, Pemetrexed; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Clinically Significant Prostate Cancer
Interventions: Not listed
Lead sponsor: Xijing Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Glioblastoma, Gliomas
Interventions: Temozolomide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 3
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York

Conditions: Breast Cancer
Interventions: Cohort 1 neo-adjuvant, Cohort 2 neo-adjuvant, Cohort 1 adjuvant, Cohort 2 adjuvant; Drug
Lead sponsor: William Sikov MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 5
States / cities: Duarte, California • New Haven, Connecticut • Providence, Rhode Island

Conditions: Bronchiolitis Obliterans Syndrome
Interventions: Not listed
Lead sponsor: Zambon SpA; Industry
Eligibility: 18 Years and older
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Cleveland, Ohio • Columbus, Ohio • Dallas, Texas

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Rocky Mountain MS Research Group, LLC; Other
Eligibility: 18 Years to 80 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Somatic Pain
Interventions: low-intensity focused ultrasound - low pressure, low-intensity focused ultrasound - medium pressure, low-intensity focused ultrasound - high pressure; Device
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Lung Cancer
Interventions: Biosensor Platform; Diagnostic Test
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ulcerative Colitis
Interventions: BI 3032950 intravenous (Part A), BI 3032950 subcutaneous (Part B); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 14
States / cities: Scottsdale, Arizona • Colorado Springs, Colorado • Kissimmee, Florida + 10 more

Conditions: Insulin Resistance
Interventions: HE3286; Drug
Lead sponsor: Harbor Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Baton Rouge, Louisiana • San Antonio, Texas

Conditions: Coronary Disease
Interventions: placebo, dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Clearwater, Florida

Conditions: Toxic Shock Syndrome Staphylococcal
Interventions: Aluminum hydroxide, STEBVax vaccine; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced, Pancreatic Adenocarcinoma Advanced or Metastatic, Lung Adenocarcinoma Metastatic, Cholangiocarcinoma Advanced, Cholangiocarcinoma Non-resectable, Mesothelin-expressing Advanced Cancers, Mesothelin-positive Advanced Malignant Solid Tumors, Colorectal Cancer
Interventions: CT-95; Drug
Lead sponsor: Context Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Denver, Colorado • Chicago, Illinois • Grand Rapids, Michigan + 4 more

Conditions: Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
Interventions: ELI-002 2P; Drug
Lead sponsor: Elicio Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more

Conditions: Glioblastoma, Gliosarcoma
Interventions: ERAS-801, ABBV-637, ABBV-155, Temozolomide, Radiotherapy; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Los Angeles, California • Miami, Florida • Indianapolis, Indiana + 8 more

Conditions: Pediatric ALL, Concussion, Mild, Concussion, Brain, Concussion, Intermediate
Interventions: Active Rehabilitation Group/Case; Behavioral
Lead sponsor: Children's National Research Institute; Other
Eligibility: 8 Years to 18 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Pancreatic Cancer, Colo-rectal Cancer, Gastric Cancer, Esophageal Cancer, Bladder Cancer, Ovarian Cancer, Abdominal Surgery Complications
Interventions: Multidisciplinary Prehabilitation Program; Behavioral
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

A Study of ERY974 in Patient With Advanced Solid Tumors

The Association Between Gut Microbiota Diversity and Postpartum Depression

IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors

Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

Endovascular Abdominal Aortic Aneurysm Repair by Interventional Cardiologists

A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab

TODAY2 Phase 2 Follow-up

Genetic Predictors of Benefit to Pembrolizumab

Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer

Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma

Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer

A Retrospective Chart Review Study of Patients With CLAD-BOS Post Lung Transplantation

Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS

Investigation of Low-intensity Focused Ultrasound Pressure

Lung Cancer Detection in Never Smokers Using Urine Volatile Organic Compound (VOCs)

A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis

Safety, Pharmacokinetics and Potential Activity of HE3286 in Obese Adult Subjects

RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome

Phase I STEBVax in Healthy Adults

CT-95 in Advanced Cancers Associated With Mesothelin Expression

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

Concussion Active Rehabilitation

Prehabilitation in High-risk Oncologic Surgery